Market Research Logo

Global Gene Therapy Partnering Terms and Agreements 2010 to 2018

Global Gene Therapy Partnering Terms and Agreements 2010 to 2018

The Global Gene Therapy Partnering Agreements 2010-2018 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in gene therapy partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Gene therapypartnering contract documents
Top gene therapy deals by value

The Global Gene Therapy Partnering Terms and Agreements 2010-2018 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Gene therapy dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Gene therapy dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Gene therapy deals since 2010. Deals are listed by headline value, signed by big pharma, most active Gene therapy dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Gene therapy dealmaking with a brief summary followed by a comprehensive listing of Gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Gene therapy technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gene therapy technologies and products.

Report scope

Global Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.

Global Gene Therapy Partnering Terms and Agreements includes:

Trends in gene therapy dealmaking in the biopharma industry since 2010
Analysis of gene therapy deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life gene therapy deals
Access to over 200 gene therapy deals
The leading gene therapy deals by value since 2010
Most active gene therapy dealmakers since 2010
The leading gene therapy partnering resources

In Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


  • Executive Summary
  • Introduction
  • Trends in Gene therapy dealmaking
    • Introduction
    • Gene therapy partnering over the years
    • Most active Gene therapy dealmakers
    • Gene therapy partnering by deal type
    • Gene therapy partnering by therapy area
    • Deal terms for Gene therapy partnering
      • Gene therapy partnering headline values
        • Table Gene therapy deals with a headline value
      • Gene therapy deal upfront payments
        • Table Gene therapy deals with an upfront value
      • Gene therapy deal milestone payments
        • Table Gene therapy deals with a milestone value
      • Gene therapy royalty rates
        • Table Gene therapy deals with a royalty rate value
  • Leading Gene therapy deals
    • Introduction
    • Top Gene therapy deals by value
      • Table Top Gene therapy deals by value since 2010
  • Most active Gene therapy dealmakers
    • Introduction
    • Most active Gene therapy dealmakers
    • Most active Gene therapy partnering company profiles
      • UniQure
      • AGTC
      • Spark Therapeutics
      • National Institutes of Health
      • Amsterdam Molecular Therapeutics
      • ReGenX Biosciences
      • Bluebird Bio
      • University of Pennsylvania
      • Foundation Fighting Blindness
      • Genethon
      • Horizon Discovery
      • Intrexon
      • Oxford BioMedica
      • Agilis Biotherapeutics
      • Asklepios Biopharmaceutical
      • Avalanche Biotechnologies
      • Genzyme
      • Lonza
      • Merck and Co
      • Orchard Therapeutics
      • Pfizer
      • RetroSense Therapeutics
      • Synpromics
      • University of Florida
      • 4D Molecular Therapeutics
  • Gene therapy contracts dealmaking directory
    • Introduction
    • Gene therapy contracts dealmaking directory
  • Gene therapy dealmaking by technology type
    • Gene therapy
  • Partnering resource center
    • Online partnering
      • Table Online partnering resources
    • Partnering events
      • Table Forthcoming partnering events
    • Further reading on dealmaking
  • Appendices
    • Gene therapy deals by company A-Z
      • 4D Molecular Therapeutics
      • AAVLife
      • Abby Grace Foundation
      • Abeona Therapeutics
      • Ablynx
      • ACGT
      • Adaptimmune
      • Addex Therapeutics
      • Advanced BioScience Laboratories
      • Advanced Biotherapeutics Consulting
      • AdVec
      • Agensys
      • Agilis Biotherapeutics
      • Agrivida
      • AGTC
      • AH Diagnostics
      • Akouos
      • Alcyone Lifesciences
      • Alder Biopharmaceuticals
      • Allegheny General Hospital
      • Allergan
      • Alliance for Regenerative Medicine
      • Alnylam Pharmaceuticals
      • ALS Finding a Cure Foundation
      • ALS Therapy Development Institute
      • Amarantus BioSciences
      • Amarna Therapeutics
      • American Association of Neuromuscular & Electrodiagnostic Medicine
      • American Gene Technologies
      • Amgen
      • AmorChem
      • Amplimmune
      • Amsterdam Molecular Therapeutics
      • AnC Bio
      • AnGes MG
      • Angionetics
      • Annapurna Therapeutics
      • Apceth
      • Applied StemCell
      • ARCA Biopharma
      • Ariad Pharmaceuticals
      • Ark Therapeutics
      • Ascenion
      • Asklepios Biopharmaceutical
      • Astellas Pharma
      • Auburn University
      • Audentes Therapeutics
      • Avacta
      • Avalanche Biotechnologies
      • Avellino Labs
      • AveXis
      • Avila Therapeutics
      • Avrobio
      • Avvinity Therapeutics
      • Axxam
      • Bachmann-Strauss Dystonia & Parkinson Foundation
      • Baxter International
      • Bayer
      • Baylor College
      • Baylor College of Medicine
      • Beijing Genomics Institute (BGI)
      • Bellicum Pharmaceuticals
      • Benitec Biopharma
      • Bio-Fortune
      • Biogen
      • BioMarin Pharmaceutical
      • BioMetrx
      • Bionic Sight
      • BioSante Pharmaceuticals
      • Bioverativ
      • Blood Systems Research Institute
      • Bluebird Bio
      • Brammer Bio
      • Bristol-Myers Squibb
      • Broad Institute
      • Butantan Institute
      • B Braun
      • B Braun CeGaT
      • California Institute for Regenerative Medicine
      • Calimmune
      • Calyxt
      • Cangene
      • Casebia Therapeutics
      • Case Western Reserve University School of Medicine
      • Cedars-Sinai Health System
      • Cedars-Sinai Medical Center
      • CeGaT
      • Celgene
      • Celladon
      • Cellectis Bioresearch
      • Cell and Gene Therapy Catapult
      • Cell Medica
      • Celtic Biotech
      • Cenix BioScience
      • Centauri Therapeutics
      • Center for Biomarker Research in Medicine
      • Cevec Pharmaceuticals
      • Chatham Therapeutics
      • CHDI Foundation
      • Chiesi Farmaceutici
      • Children's Hospital Boston
      • Children's Hospital of Philadelphia
      • Children's Hospital of Pittsburgh
      • Children's Research Institute
      • Chromatin
      • Cincinnati Children's Hospital Medical Center
      • City of Hope
      • Clearside Biomedical
      • Clovis Oncology
      • CMC Biologics
      • Cobra Biologics
      • Cohen-McNiece Foundation
      • Columbia University
      • Concord Medical Services Holdings
      • CRISPR Therapeutics
      • Crucell
      • CryoPort
      • Cystic Fibrosis Foundation
      • Cystic Fibrosis Foundation Therapeutics
      • Daiichi Sankyo
      • Dana-Farber Cancer Institute
      • DeCODE Genetics
      • Defyrus
      • Digna Biotech
      • Dimension Therapeutics
      • Dnastar
      • Dr. Reddy's Laboratories
      • Duke Clinical Research Institute (DCRI)
      • Duke University
      • DuPont
      • Eden Biodesign
      • Edimer Pharmaceuticals
      • Editas Medicine
      • EGen
      • Eiger BioPharmaceuticals
      • Emory University
      • Enginasion
      • Enterprise Partners Venture Capital
      • EnVivo Pharmaceuticals
      • Errant Gene Therapeutics
      • European Commission
      • European Union
      • Evogene
      • Fate Therapeutics
      • Federal Ministry of Education and Research (BMBF)
      • Fibrocell Science
      • Fidelity Biosciences
      • FIT Biotech
      • Five Prime Therapeutics
      • FKD Therapies
      • Fluidigm
      • Fondazione Telethon
      • Food and Drug Administration (FDA)
      • Foundation Fighting Blindness
      • Foundation Medicine
      • Fovea Pharmaceuticals
      • Fox Chase Cancer Center
      • French Muscular Dystrophy Association
      • Friedreichs Ataxia Research Alliance
      • Galapagos
      • Genable Technologies
      • Genethon
      • Genetic Information Research Institute
      • Gene Therapy Research Institution
      • GenOway
      • GenStem Therapeutics
      • Genzyme
      • Georgetown University
      • Georgetown University Medical Center
      • George Washington University
      • Geospiza
      • GeoVax
      • Gladstone Institutes
      • GlaxoSmithKline
      • Golden Helix
      • Great Ormond Street Hospital (GOSH)
      • Harvard Medical School
      • Harvard School of Public Health
      • Helmholtz Zentrum Munchen
      • Horizon Discovery
      • HTG Molecular Diagnostics
      • Huapont Pharma
      • Human BioMolecular Research Institute
      • Icagen
      • Icahn School of Medicine at Mount Sinai
      • Immune Pharmaceuticals
      • Indivumed
      • Innovate UK
      • Institute for Translational Oncology Research
      • Institut Pasteur
      • Integrated DNA Technologies
      • International Duchenne Alliance
      • International Medical Center
      • Intrexon
      • Ipsen
      • ISIS Innovation
      • Israeli National Authority for Technological Innovation
      • Janssen Biotech
      • Janssen Pharmaceuticals
      • Japan Tobacco
      • Jiangsu Hengrui Medicine
      • Johnson & Johnson Innovation
      • Johns Hopkins University
      • Juno Therapeutics
      • Kadmon Pharmaceuticals
      • Kangmei Pharma
      • Kite Pharma
      • Kogenix
      • KWS SAAT
      • Lab21
      • Laboratory of Neurobiology and Gene Therapy
      • Lawrence Berkeley National Laboratory
      • Lee Moffitt Cancer Center
      • Lentigen
      • Life Technologies Corporation
      • Lonza
      • Lysogene
      • Maria Curie-Sklodowska University
      • Maryland Stem Cell Research Fund
      • Massachusetts Eye and Ear Infirmary
      • Massachusetts General Hospital
      • Max-Delbruck Center for Molecular Medicine
      • Mayo Clinic
      • McKesson
      • MD Anderson Cancer Center
      • Medac
      • Medgenics
      • Medical College of Wisconsin
      • Medical Research Council
      • Medifocus
      • MediGene
      • Medison Pharma
      • Medtronic
      • MeiraGTx
      • Memorial Sloan Kettering Cancer Center
      • Merck and Co
      • Merck Serono
      • Merck Sharpe & Dohme
      • Mesoblast
      • Methodist Hospital Houston
      • Michael J Fox Foundation
      • Milo Biotechnology
      • Miltenyi Biotec
      • Mitsubishi Tanabe Pharma
      • MolMed
      • Monsanto
      • Morphogenesis
      • MorphoSys
      • Muscular Dystrophy Association
      • Myriad Genetics
      • NanoString Technologies
      • Nanotechnology Characterization Laboratory
      • National Cancer Institute
      • National Center for Advancing Translational Sciences (NCATS)
      • National Eye Institute
      • National Heart, Lung and Blood Institute
      • National Human Genome Research Institute
      • National Institutes of Health
      • National Institute of Allergy and Infectious Diseases
      • National Institute of Dental and Craniofacial Research (NIDCR)
      • National Institute of Neurological Disorders and Stroke
      • National Institute of Standards and Technology
      • National Taiwan University Hospital
      • National University of Ireland, Galway (NUI Galway)
      • Nationwide Children's Hospital
      • NightstaRx
      • Nightstar Therapeutics
      • Northwestern University
      • Novartis
      • Novasep
      • Numerate
      • Nuron Biotech
      • Ocugen
      • Ohio State University
      • Oklahoma University Health Sciences Center
      • Oncodesign
      • Oncolys BioPharma
      • OncoSec Medical
      • OpGen
      • Ophthotech
      • Orchard Therapeutics
      • Oxford BioMedica
      • Oxford Nanopore Technologies
      • PACA Inovation
      • Pall Corporation
      • Paragon Bioservices
      • Parent Project Muscular Dystrophy
      • Paul Ehrlich Institute
      • PCT
      • Peptineo
      • Pfizer
      • PharmaCell
      • Pioneer Hi-Bred
      • PlasmaTech Biopharmaceuticals
      • PlasmidFactory
      • Population Diagnostics
      • Precision BioSciences
      • PreveCeutical Medical
      • Prostate Cancer Foundation (PCF)
      • Proteacel
      • Protein Sciences
      • Proteonomix
      • Proteostasis Therapeutics
      • Provecs Medical
      • PsiOxus Therapeutics
      • PTC Therapeutics
      • Quark Pharmaceuticals
      • Radboud University Nijmegen Medical Centre
      • Radient Pharmaceuticals
      • Regeneron Pharmaceuticals
      • Regenxbio
      • ReGenX Biosciences
      • ReNeuron
      • Renova Therapeutics
      • Renovo
      • Research Development Foundation
      • Response Genetics
      • RetroSense Therapeutics
      • Roche
      • SAFC
      • Saga Investments
      • SAIC-Frederick
      • Salk Institute
      • Sanford Burnham Institute
      • Sangamo BioSciences
      • Sanofi
      • San Raffaele Telethon Institute for Gene Therapy
      • Sarepta Therapeutics
      • Scarab Genomics
      • Schepens Eye Research Institute
      • Scottish Enterprise
      • Selecta Biosciences
      • Servier
      • Shenzhen Yuanxing Bio-Pharm Science & Technology
      • Siemens Healthcare
      • Sigma Life Science
      • SinoBiotech
      • Sirion Therapeutics
      • Sitoa
      • Sloning BioTechnology
      • Spark Therapeutics
      • Spooner Girls Foundation
      • St. Jude Children's Research Hospital
      • Stanford University
      • StemedicaAnC
      • Stemedica Internaional
      • StrideBio
      • St Jude Medical
      • Sun Pharmaceutical
      • SwitchGear Genomics
      • Synpromics
      • Synthetic Genomics
      • System Biosciences
      • T-TOP Clinical Research
      • Takara Bio
      • TapImmune
      • Target ALS Foundation
      • Taxus Cardium Pharmaceuticals
      • Team Sanfilippo
      • Teva Pharmaceutical Industries
      • Texas Children's Hospital
      • Theragene Pharmaceuticals
      • Thermo Fisher Scientific
      • The Cell and Gene Therapy Unit
      • The Cyprus Institute of Neurology and Genetics
      • The Parker Institute For Cancer Immunotherapy
      • TissueGene
      • Tocagen
      • Touchlight
      • TransCytos
      • Transposagen Biopharmaceuticals
      • Treeway
      • Tufts Medical Center
      • Two Blades Foundation
      • TxCell
      • Ugichem
      • UK Cystic Fibrosis Gene Therapy Consortium
      • Ulster University
      • UNeMed
      • UniQuest
      • UniQure
      • Universite Laval
      • University College London
      • University Gottingen
      • University Hospitals Case Medical Center
      • University of Alabama
      • University of Barcelona
      • University of British Columbia
      • University of California, Davis
      • University of California, San Diego
      • University of California Irvine
      • University of California Los Angeles
      • University of California San Francisco
      • University of Florida
      • University of Iowa
      • University of Kentucky
      • University of Lausanne
      • University of Manchester
      • University of Massachusetts
      • University of Massachusetts Medical School
      • University of Medicine and Dentistry of New Jersey
      • University of Nebraska
      • University of North Carolina
      • University of Oklahoma
      • University of Oxford
      • University of Pennsylvania
      • University of Pittsburgh Medical Center
      • University of Quebec
      • University of Rome
      • University of South Carolina
      • University of South Florida
      • University of Washington
      • University of Western Australia
      • Vaccine and Gene Therapy Institute of Florida (VGTI-FL)
      • VBL Therapeutics (dba)
      • VGX International
      • Virginia Biosciences Health Research Corporation
      • Vision Institute
      • VITRUVIAN BioMedical
      • Voyager Therapeutics
      • Wake Forest University School of Medicine
      • Wayne State University
      • Weill Cornell Medical College
      • Weizmann Institute
      • Wellcome Trust
      • Wellcome Trust Sanger Institute
      • Wuxi Apptec Laboratory Services
      • Xencor
      • Xenon Pharmaceuticals
      • Yeda Research and Development Company
      • Ziopharm Oncology
    • Gene therapy deals by stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Regulatory
      • Marketed
      • Formulation
    • Gene therapy deals by deal type
      • Asset purchase
      • Assignment
      • Bigpharma outlicensing
      • Co-development
      • Collaborative R&D
      • Co-market
      • Co-promotion
      • CRADA
      • Cross-licensing
      • Development
      • Distribution
      • Equity purchase
      • Evaluation
      • Grant
      • Joint venture
      • Licensing
      • Litigation
      • Manufacturing
      • Marketing
      • Option
      • Research
      • Spin out
      • Sub-license
      • Supply
      • Technology transfer
      • Termination
    • Gene therapy deals by therapy area
      • Cardiovascular
      • Angina
      • Atrial fibrillation
      • Long QT syndrome
      • Atherosclerosis
      • Congestive heart failure
      • Hypercholesterolemia
      • Limb ischemia
      • Myocardial Infarction
      • Peripheral arterial disease
      • Central Nervous System
      • Epilepsy
      • Migraine
      • Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease)
      • Multiple sclerosis
      • Pain
      • Parkinson's disease
      • Dental caries
      • Xerostomia
      • Inflammatory bowel disease
      • Crohn's disease
      • Ulcerative colitis
      • Pancreatitis
      • Genetic disorders
      • Cystic Fibrosis (CF)
      • Hereditary angioedema
      • Huntington's disease
      • Rare genetic disorders
      • Sickle cell disease
      • Renal failure
      • Human papillomavirus (HPV)
      • Hematology
      • Hemophilia
      • Neutropenia
      • Thalassemia
      • Surgery
      • Transplantation
      • Immunology
      • AIDS
      • Allergy
      • Inflammation
      • Infectives
      • Fungal
      • Dengue fever
      • Viral
      • Ebola
      • HIV
      • Influenza
      • Metabolic
      • Diabetes
      • Type 1
      • Type 2
      • Phenylketonuria
      • Liver disease
      • Lysosomal storage disorders
      • Musculoskeletal
      • Arthritis
      • Osteoarthritis
      • Bone fracture
      • Muscular dystrophy
      • Spinal muscular atrophy
      • Obstetrics
      • Fetal abnormalities
      • Prenatal screening
      • Oncology
      • Bladder cancer
      • Brain cancer
      • Breast cancer
      • Colorectal cancer
      • Esophageal cancer
      • Gastric cancer
      • Head and neck cancer
      • Leukemia
      • Acute lymphoblastic leukemia
      • Liver cancer
      • Lung cancer
      • Lymphoma
      • Melanoma
      • Metastases
      • Multiple myeloma
      • Ovarian cancer
      • Pancreatic cancer
      • Prostate cancer
      • Solid tumors
      • Ophthalmics
      • Age-related macular degeneration
      • Blindness
      • Diabetic macular edema
      • Glaucoma
      • Retinal detachment
      • Retinopathy
      • Diabetic retinopathy
      • Orphan disease
      • Pediatrics
      • Dementia
      • Alzheimers
      • Dystonia
      • Autism
      • Obesity
      • Respiratory
      • Hearing disorders
      • Hearing loss
      • Meniere's disease
      • Candida albicans (Thrush)
    • Deal type definitions
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report